329 related articles for article (PubMed ID: 36387865)
21. Targeting heterogeneity of adrenocortical carcinoma: Evaluation and extension of preclinical tumor models to improve clinical translation.
Hantel C; Shapiro I; Poli G; Chiapponi C; Bidlingmaier M; Reincke M; Luconi M; Jung S; Beuschlein F
Oncotarget; 2016 Nov; 7(48):79292-79304. PubMed ID: 27764813
[TBL] [Abstract][Full Text] [Related]
22. TP53 germline mutations in adult patients with adrenocortical carcinoma.
Herrmann LJ; Heinze B; Fassnacht M; Willenberg HS; Quinkler M; Reisch N; Zink M; Allolio B; Hahner S
J Clin Endocrinol Metab; 2012 Mar; 97(3):E476-85. PubMed ID: 22170717
[TBL] [Abstract][Full Text] [Related]
23. Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: a children's oncology group study.
Wasserman JD; Novokmet A; Eichler-Jonsson C; Ribeiro RC; Rodriguez-Galindo C; Zambetti GP; Malkin D
J Clin Oncol; 2015 Feb; 33(6):602-9. PubMed ID: 25584008
[TBL] [Abstract][Full Text] [Related]
24. Diagnosis, treatment and outcome of adrenocortical cancer.
Mihai R
Br J Surg; 2015 Mar; 102(4):291-306. PubMed ID: 25689291
[TBL] [Abstract][Full Text] [Related]
25. Clinical presentation, treatment modalities and outcome in patients with adrenocortical carcinoma: A single center experience.
Bronswijk MJH; Laenen A; Bechter OE
Neoplasma; 2020 Jan; 67(1):209-213. PubMed ID: 31777255
[TBL] [Abstract][Full Text] [Related]
26. Long-Term Survival in a Patient With Metastatic DDR2-Positive Adrenal Cortical Carcinoma.
Taza F; Chovanec M; Hahn N; Albany C
Clin Genitourin Cancer; 2017 Oct; 15(5):e893-e895. PubMed ID: 28606737
[No Abstract] [Full Text] [Related]
27. Prevalence of germline TP53 mutations in a prospective series of unselected patients with adrenocortical carcinoma.
Raymond VM; Else T; Everett JN; Long JM; Gruber SB; Hammer GD
J Clin Endocrinol Metab; 2013 Jan; 98(1):E119-25. PubMed ID: 23175693
[TBL] [Abstract][Full Text] [Related]
28. Future directions in the diagnosis and medical treatment of adrenocortical carcinoma.
Creemers SG; Hofland LJ; Korpershoek E; Franssen GJ; van Kemenade FJ; de Herder WW; Feelders RA
Endocr Relat Cancer; 2016 Jan; 23(1):R43-69. PubMed ID: 26475053
[TBL] [Abstract][Full Text] [Related]
29. [Adrenocortical carcinoma and its treatment].
Tupikowski W; Bednarek-Tupikowska G; Florczak A
Postepy Hig Med Dosw (Online); 2004 Feb; 58():27-36. PubMed ID: 15069374
[TBL] [Abstract][Full Text] [Related]
30. Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer.
Berruti A; Terzolo M; Pia A; Angeli A; Dogliotti L
Cancer; 1998 Nov; 83(10):2194-200. PubMed ID: 9827725
[TBL] [Abstract][Full Text] [Related]
31. Adrenocortical carcinoma.
Baudin E;
Endocrinol Metab Clin North Am; 2015 Jun; 44(2):411-34. PubMed ID: 26038209
[TBL] [Abstract][Full Text] [Related]
32. Adrenal cortical neoplasms in children: why so many carcinomas and yet so many survivors?
Dehner LP; Hill DA
Pediatr Dev Pathol; 2009; 12(4):284-91. PubMed ID: 19326954
[TBL] [Abstract][Full Text] [Related]
33. A novel p.Gly187Arg TP53 variant appears to result in Li-Fraumeni syndrome.
Doyle MR; Johnston JM
Pediatr Hematol Oncol; 2018 Apr; 35(3):203-207. PubMed ID: 30239254
[TBL] [Abstract][Full Text] [Related]
34. Clinical management of adrenocortical carcinoma.
Fassnacht M; Allolio B
Best Pract Res Clin Endocrinol Metab; 2009 Apr; 23(2):273-89. PubMed ID: 19500769
[TBL] [Abstract][Full Text] [Related]
35. Next-generation therapies for adrenocortical carcinoma.
Altieri B; Ronchi CL; Kroiss M; Fassnacht M
Best Pract Res Clin Endocrinol Metab; 2020 May; 34(3):101434. PubMed ID: 32622829
[TBL] [Abstract][Full Text] [Related]
36. Mitotane associated with cisplatin, etoposide, and doxorubicin in advanced childhood adrenocortical carcinoma: mitotane monitoring and tumor regression.
Zancanella P; Pianovski MA; Oliveira BH; Ferman S; Piovezan GC; Lichtvan LL; Voss SZ; Stinghen ST; Callefe LG; Parise GA; Santana MH; Figueiredo BC
J Pediatr Hematol Oncol; 2006 Aug; 28(8):513-24. PubMed ID: 16912591
[TBL] [Abstract][Full Text] [Related]
37. Expression of SOAT1 in Adrenocortical Carcinoma and Response to Mitotane Monotherapy: An ENSAT Multicenter Study.
Weigand I; Altieri B; Lacombe AMF; Basile V; Kircher S; Landwehr LS; Schreiner J; Zerbini MCN; Ronchi CL; Megerle F; Berruti A; Canu L; Volante M; Paiva I; Della Casa S; Sbiera S; Fassnacht M; Fragoso MCBV; Terzolo M; Kroiss M
J Clin Endocrinol Metab; 2020 Aug; 105(8):. PubMed ID: 32449514
[TBL] [Abstract][Full Text] [Related]
38. Adrenocortical Cancer: A Molecularly Complex Disease Where Surgery Matters.
Payabyab EC; Balasubramaniam S; Edgerly M; Velarde M; Merino MJ; Venkatesan AM; Leuva H; Litman T; Bates SE; Fojo T
Clin Cancer Res; 2016 Oct; 22(20):4989-5000. PubMed ID: 27742785
[TBL] [Abstract][Full Text] [Related]
39. Adrenocortical carcinoma: Diagnosis, prognostic classification and treatment of localized and advanced disease.
Libé R; Huillard O
Cancer Treat Res Commun; 2023; 37():100759. PubMed ID: 37690343
[TBL] [Abstract][Full Text] [Related]
40. Decision-making for adrenocortical carcinoma: surgical, systemic, and endocrine management options.
Puglisi S; Perotti P; Cosentini D; Roca E; Basile V; Berruti A; Terzolo M
Expert Rev Anticancer Ther; 2018 Nov; 18(11):1125-1133. PubMed ID: 30117750
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
